Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice one. I'm in with a 14$ average, soon to be out and happy I waited. Sold cpxx way too soon. a few of these make for a good year!
That was a great sequence in the SF-Red Sox game.
Reminds me of a AA game I saw a few years ago. The batters on one team were consistently calling time out as the opposing pitcher was going into his wind up. Really ruffling the pitcher's feathers....After about 5 of these time outs, the next hitter up calls for time out on the first pitch, which is granted by the ump. The pitcher doesn't even pause in his wind up- just keeps it coming and drills the batter in the ass with a heater as he's stepping away from the plate! Before the ump knew what was happening, the pitcher dropped his glove like a hockey player and charged the plate! Both benches cleared.
I love this game!
RLYP
It's been a great ride! Congrats to all still holding.
http://finance.yahoo.com/news/galenica-relypsa-announce-agreement-galenica-050000854.html
Little picture managerial moves by Collins are the least of the Mets woes. The Cards look fantastic- healthy and ready for the 2nd half...especially if they can sort out Rosenthal. They may actually catch the Cubs if the chips fall perfectly.
WCs are going to get a bit harder to come by in 2016- the Dodgers are going to be there and the Pirates can't be discounted.
A huge part of the Mets sucess in the 2nd half last season was the Nats implosion. That won't happen again this season with Dusty at the helm.
Get used to it. Rangers pitching? What's after Hamels?
In at $1.98 today. I can wait. There's way too much wrong with the short term world picture to think markets can climb higher on any steady basis. DOW 18,000 seems like a pretty solid barrier.
And looking at the bigger economic picture, what a mess....
Garza gives up 7 earned in 4.1 for the Crew. This is a guy who couldn't wait to bag the Cubs on his way out of Chicago:
http://espn.go.com/chicago/mlb/story/_/id/10847460/matt-garza-says-jeff-samardzija-needs-pitch-way-chicago-cubs
Forget about evaluating young talent, the true test of a great GM is how well you can offload bloated, garbage contracts like Garza'a without having to cover too much of the contract yourself.....Guys like Garza, Howard, Sandoval give new meaning to the concept of "untouchable" when it comes to trade time.
Sadly for small market teams, unlike say, the Dodgers who can eat Kemp's $$, they're stuck with the reality of overpaying for the dregs of the free agent player pool- mediocre or worse arms and bats that nobody wanted in the first place. You could make an excellent mock All-Star team from these chumps.
Desmond is having a great season but MVP? Spoken like a true hardcore fan! Bummer the Rangers will flail in the 2nd half and struggle to secure a WC spot!
I can think of a few other candidates who would dispute that MVP claim: Machado, Encarnacion, Ortiz, Altuve off the top of my head.
Did you catch that weak, 9th inning dribbler against the Brewers that somehow found a way through Murphy's legs...the grounder that my 7 year old daughter makes 99.9% of the time? Maybe Zobrist is the better choice, lol.
Nats would roll if the the Cubs starters pitch like they have been lately. Wow, talk about a serious crash back to earth.
Looks like my Brewers have positioned themselves nicely to offload Braun before the deadline. They look like the best of the rebuilding teams this year, with the Phils streaking in there from time to time.
Not to mention Murphy's bat has carried that team since Harper cooled off. Zobrist has a bit more support around him, both in the infield and in the line up.
Looks like Cubs fans are still holding a grudge against Murph for crushing them in the pennant last year.
The hits keep on coming:
http://www.espn.com.au/mlb/story/_/id/16593005/new-york-mets-pitchers-noah-syndergaard-steven-matz-bone-spurs-gm-says
The problem with you Mets fans is that inevitable sense of entitlement following last season's quasi-Amazin' run. We don't have that trouble in Milwaukee!
Fair to say that the chips fell pretty sweetly for the Mets in 2015...It could have been a much, much worse season in Metland in 2015, but not a whole lot better.
Mets looking more and more like the Brewers except with a pitching staff...and now a wife beater.
I guess we'll see in November, lol. Looks like the pendulum has peaked on its upward swing toward multi-national corporate dominance and is starting its swing back toward countries looking out for themselves...and hopefully their workers.
CPT Matt, didn't know about the "Cable" but laid in a strong position in SDOW (3x bear ETF) about a week ago and off-loaded some highly speculative bio's which have proven as fun (and fruitful) as the roulette wheel. I'm sure there will be some money to be made out of all of this, but I plan to watch from the sideline until the water is calm enough for minnows to return.
Doubtful IMO. a falling tide lowers all ships....unless they have golden hulls.
The market has been angling for a correction and this is not a one-off catalyst. The follow-on impact on international markets will take years to play out as other EU members stampede to see who can exit first and fastest.
I just can't believe this is happening so soon after the 10's of millions of Europeans who died in 20th century nation-state wars....
Trouble in Met as Collins circles the wagons as panic sets in:
http://espn.go.com/mlb/story/_/id/16344209/manager-terry-collins-vows-shake-struggling-new-york-mets
ADMP
No questioning BobStocks succinct and accurate analysis that this one's a real poodle. Can't help you with the cash numbers. This is from their latest 8-k:
The Company is reviewing the CRL and plans to request a meeting with the FDA to discuss the CRL. Depending in part on the results of subsequent communications with the FDA, development of a protocol acceptable to the FDA for the additional studies, and the results of any additional studies that the Company may conduct, the Company believes that it can complete the additional testing and submit the results to the FDA sometime in the second half of 2016, although there can be no assurances that this will be the case.
And this is from their post CRL PR:
The Company believes that it can finalize the study protocols with the FDA and complete the additional testing within a relatively short period of time at an immaterial cost, and submit the data back to the FDA sometime in the second half of 2016.
It's quite understandable that this management has lost all credibility with both the big end of the street and retail.
In general, these are some tough days for bounce plays in the market, but especially in bio's.
My plan is to hold shares through the next FDA approval run up, which I have to believe will exceed my cost basis of $3.70.
Also added RVNC today at $13.40; again, willing to hold for a year.
They must have a plan if hey think it will rise organically
"Rise organically" is code for "we here within the company are not going to do squat to try and boost the PPS"
MRNS sold pre-market yesterday at $2.20 for a huge loss ($5.65 buy in, how many times must I learn this lesson?).
RVNC eyeing a position today as the company cratered %25 after announcing a failed study topical gel to treat crow's feet after hours:
http://www.marketwatch.com/story/revance-shares-drop-after-crows-feet-treatment-study-fails-2016-06-13?siteid=yhoof2
Lightening up in general; IMO between the DOW topping out at 18,000...with the US economy as bleak as it it truly is, how much higher can the DOW be expected to climb?... and the brexit fear, there's a lot of downside pressure ahead.
With all due respect to the Mets shabby line-up, your boys ran into the brew-crew buzz saw!! 19-17 at home, 3 games under .500
We ain't talkin' about the Braves here! The first series between these 2 teams was close as well, with the crew letting a couple slip away.
It's looking a lot like last year in Mets land but for different reasons. Wright on the DL this year was completely predictable, D'Arnaud is a defensive liability and was never counted on to carry much offense anyway and Duda, yeah, well everyone has injuries in a 162 game season.
The HUGE upside to this year's Mets line up was of course Cespedes' decision to play in NY, a windfall they certainly didn't anticipate as evidenced by the DeAza signing, so on the whole, Mets' fans have very little to complain about on the roster front.....Now management? That's a different story but the same ol' same ol' in Flushing.
Careful you don't shoot him!
ADMP
Added ADMP today at $3.80. IMO the CRL is a very manageable setback and the huge drop in PPS is a fantastic buying op. Near term catalyst?
The Company believes that it can finalize the study protocols with the FDA and complete the additional testing within a relatively short period of time at an immaterial cost, and submit the data back to the FDA sometime in the second half of 2016. It should be noted that the Company has successfully completed the “volume delivery” issue that was associated with the initial CRL.
IMO this is easy money in a bio market that is getting harder and harder to handicap on the long side.
Another tough loss for the White Sox. Looks like the Latos miracle has run its course...how long til they fire Ventura?
Sold TCON on positive trial data (small pool) at $7.45 from $6.50 entry. Definitely one to watch for the back half of 2016.
Sold TTNP on Monday at $6.00 from $5.65 pre-approval purchase. What a horrible stock for retail to trade....driven into the ground by its own masters who couldn't sell fast enough and don't appear to be done yet.
Holding:
MRNS- very nice pop today. Company is on the verge of revealing Fragile X trial news. Yup, a binary event but like the risk/reward here as MRNS has many irons in the fire in the CNS field.
EDAP- yawn.
Watching:
CERU, ARLZ
I agreed . I closed my position at the open...shares from pre-approval bought at $5.65....
One consistency with TTNP over the years has been its completely eff-ed up trading patterns. This company has traded like sweaty dog's balls since I've been following it.
I'm over trying to justify whether it's shorts, FDA conspiracy, big pharma conspiracy, management incompetence, diabolical partners or a toxic blend of all of the above.
GLTA still holding here.
MRNS $5.55 Bought a full position yesterday at $5.55
Link back for upcoming catalyst news. From their May PR:
The Company is on-track to report top-line data in the upcoming weeks from the Phase 2 proof-of-concept, investigator-sponsored clinical study in patients with Fragile X syndrome. The study incorporates several clinician- and parental-validated scales to evaluate the effect of ganaxolone on anxiety, attention, social behavior, aggression, hyperactivity, and language.
The Company is on-track to report top-line data in the middle of 2016 from the Phase 3 clinical trial evaluating ganaxolone in adults with focal onset seizures.
The Company is on-track to report top-line data in the middle of 2016 from the Phase 2, proof-of-concept clinical trial evaluating ganaxolone in pediatrics with PCDH19.
At March 31, 2016, the Company had cash, cash equivalents and investments of $51.4 million, compared to $57.7 million at December 31, 2015. The Company believes that its cash, cash equivalents and investments, as of March 31, 2016, are adequate to fund operations into the second half of 2017.
ESOA Love that divvy! Insiders collecting the bonus scooby snack. Who needs a share buy back, lol?
Yup, that was a horrible bit of managing. The guy was a lefty to boot! Looking like a long year in LA. Kershaw has to go 9 to win these days...and chip in an RBI to get over the line in the close ones.
The pen reminds me of the Tigers pen when they were stacked with Verlander, Scherzer and Price, even though Jansen is a blue chip closer. Solid as a bowl of jello.
They're going to be looking up at Bochy's boys all year...and scrambling for a WC come September.
Shows great leadership from the true leader of Probuphine.
Could not agree more. IMO part of the sluggishness in the PPS on Friday following approval comes from a lack of confidence in TTNP management itself. The reality is that it took Braeburn to get Probuphine over the FDA approval line. What's now left in the TTNP pipeline?
Braeburn has a vision for success, but more importantly, they have a clear plan for getting there. The fact that Sunil and co are attached to Braeburn via royaly payments could very well be TTNP's saving grace. After all, with Probuphine approval in the bag, who's going to buy into TTNP for their exciting, well-planned next project (he said sarcastically)...Alzheimers or whatever it might turn out to be.
And based on the TTNP track record, is there any doubt that Sunil can spend through those Braeburn royalty payments quicker than shit through a goose whilst he banks a hefy paycheck?
IMO, a buyout at any price over $15 would be a happy ending to this story fort those of us still holding. As I consider the revenue projections around Probuphine, I can only wish that I had shares in a publically traded Braeburn rather than TTNP.
TCON
Bought a full position of TCON at $6.50. MC of $79 million, 12.2 million O/S
Company has traded to a high of $18.35 in the past year and now sits at the lower end of the 52 week low of $5.88
-Lots of approved drugs to pair in trials with TRC105, TCON's key Endoglin Antibody
-Partnered with Santen in wet AMD ($10 million upfront payment, potentiallly $155 million in milestone payments)
- Strong collaboration with the National Cancer Institute
From the Q1 update:
Three data presentations at the American Society of Clinical Oncology Annual Meeting in June:
Survival data stratified by tumor endoglin expression from the Phase 1b/2 study of the combination of TRC105 and Votrient in soft tissue sarcoma patients, including in an expanded cohort of patients with angiosarcoma.
Overall survival data from the Phase 2 study of the combination of TRC105 and Avastin in Avastin-refractory glioblastoma patients.
Data from the Phase 1 study of the combination of TRC102 and Temodar in refractory solid tumor patients.
- See more at: www.publicnow.com/view/2D364BAD689BB7AC5FA396C1E2A1E4E7395CC6B4#sthash.FJl5kudP.dpuf
'We continue to achieve important clinical progress across our pipeline, and remain on track to initiate our first Phase 3 pivotal study of TRC105 later this year,' said Charles P. Theuer, M.D., Ph.D., President and CEO of TRACON. 'This should be a transformative year for TRACON, as we expect to deliver on a number of key milestones, including multiple Phase 2 data readouts across several indications. - See more at: www.publicnow.com/view/2D364BAD689BB7AC5FA396C1E2A1E4E7395CC6B4#sthash.FJl5kudP.dpuf
$45 million in the bank, ($10 million in debt) which CEO states should see them through all of the P2 trials in 2016.
TCON saw a nice pop in the PPS after ASCO 2105.
I strongly recommend listening to the CEO presentation on May 23, 2016 at the UBS Global Healthcare Conference.
http://ir.traconpharma.com/phoenix.zhtml?c=253885&p=irol-calendar
NERV. All out 1100 shares premarket at 10.15 from 3.45 entry yesterday.
Good luck folks. Here's why I'm holding through the decision:
1. ADCOM 10-4 CRL
2. Follow up phase 3 study very positive
3. ADCOM II 12-5
4. PDUFA decision delayed from Feb 2016 until tomorrow
IMO, there will not be another delay from the FDA. 3 years is a pretty fair time to come to a decision, even from the likes of the FDA.
I usually never hold through FDA decidions, but TTNP has already been through the CRL, the confirmatory trial and the REMS/labelling delay. I can't see how, given the consistently strong evidence around the efficacy as shown in all the trials, the FDA can block approval.
With a market cap of less than $430 million, or 3X today's share price, TTNP is worth better than $20 a share. That's a pretty decent risk/reward scenario IMO.
TRUTH, thanks for your incredible input on this board. Braeburn would have been wise to hire you as their IR/PR honcho!!!
Thanks for the update and enjoy the time in SA. What a destination!
I'm currently holding:
CYDY- like the June 20 news date here. Loads of hype but not without hope
TTNP- a full position I will hold through the FDA announcement, which has been been a bad idea in the past for me, but I've been watching this one for years and think it's the rare PDUFA decision where the risk of holding through the decision is worth it
EDAP- way too cheap at this price, with a great quarterly report recently released: http://ih.advfn.com/p.php?pid=nmona&article=71514604
ARLZ- have traded this one a few times between $3.60 and $4.20 around a core position
Watching closely:
ELTP- July 14 PDUFA, mired in a .31-34 channel
NERV- data due from 2 phase II's CNS trials in Q2. Recently a director bought loads of shares st $5.75 a pop. Warrants also recently exercised at about the same price. This one is so far under the radar that not a single question was asked after the last earnings call. Caveat: the PPS has tumbled off the cliff in the past few trading sessions (albeit on lowish volume)...almost like someone knows the P2 results may not be so hot....
Yup, the Red Sox look incredible this year. Porcello finally has come around after a wretched 2015, and if they get something out of Kelly, the division is theirs to lose.
Good to see the Cubs come back to earth a bit too.
I think the jury's still out on the Granderson contract. 4 years 60 million isn't too horrific if the guy pulls his head out this year. If not, basically the Mets paid 60 million for 1 decent, not great, 2015 season...not to mention the win/loss opportunity cost involved in trotting out a .220 hitter for 3 out of 4 years....not to mention the money which could have paid for someone else to man the outfield....Beane, Bonilla, Bay, Granderson....anyone else see a pattern here? At least Sandy pulled the plug on the Carlos Gomez deal last year...maybe Braun this year....?
We'll see how the season ends, but at this point, it looks like the Yanks wasted less on Beltran than the Mets did on Granderson!
Yup, Bautista took a rock-solid shot. I can't believe he stayed on his feet. The replay shows just how stunned he was after reeling back a few steps.
Odor has to go. 25 games minimum. A little pushy-shovey is different than cold-cocking a guy in the choppers.
Started a fat position here, albeit a bit too early in the day ($5.50). I'll hold this one through approval news; I can't see the FDA denying the strong evidence a 2nd time, especially with the lack of viable treatment alternatives to the drug OD crisis in America.
If a better treatment for opioid dependence comes along in the future and displaces Probuphine, so be it. That's what markets are for.
Until that time, my $$ is on TTNP. Braeburn has crossed the t's and dotted the i's on the PDUFA app this time around. IMO, whatever objections the FDA might have to approval, they have nothing to do with efficacy, and that's what's imperative when dealing with addiction.
I don't own it!